- Report
- August 2023
- 118 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- April 2020
Global
From €3885EUR$4,000USD£3,351GBP
- Report
- April 2023
- 120 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- September 2021
- 40 Pages
China
From €2525EUR$2,600USD£2,178GBP
- Report
- March 2018
- 34 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Report
- April 2023
- 73 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Report
- April 2024
- 50 Pages
Global
From €2574EUR$2,650USD£2,220GBP
- Report
- April 2024
- 50 Pages
Global
From €2574EUR$2,650USD£2,220GBP
- Report
- March 2020
Japan, United States, ... Japan, United States, Europe
From €1408EUR$1,450USD£1,215GBP
- Report
- June 2023
- 280 Pages
Global
From €5565EUR$5,730USD£4,801GBP
Dabigatran is a direct thrombin inhibitor used in the treatment of hematological diseases. It is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Dabigatran is a novel anticoagulant that has been approved for use in the United States, Europe, and other countries. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, a protein involved in the clotting process.
The dabigatran market is highly competitive, with several companies offering products in the space. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Sanofi. Other companies in the market include Daiichi Sankyo, Bayer, and GlaxoSmithKline. Show Less Read more
